Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, withdrew its plans for an initial public offering on Friday. It had filed to raise $25 million by offering 2.8 million shares (2% secondary) at a price range of $8 ...read more
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more
Two blank check companies debuted this week, while two IPOs and three SPACs submitted initial filings. Also on the SPAC side, Soulpower Acquisition (SOUL) announced it would merge with SWB Holdings at a proposed $8.1 billion valuation, one of the largest...read more
Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The Menlo Park, CA-based company plans to raise $25 million by offering 2.8 ...read more
Phase 2 oncology biotech Edison Oncology withdraws $25 million IPO
Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, withdrew its plans for an initial public offering on Friday. It had filed to raise $25 million by offering 2.8 million shares (2% secondary) at a price range of $8 ...read more
Renaissance Capital's November IPO Market Update
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more
US IPO Weekly Recap: IPO market quiet in short Thanksgiving week
Two blank check companies debuted this week, while two IPOs and three SPACs submitted initial filings. Also on the SPAC side, Soulpower Acquisition (SOUL) announced it would merge with SWB Holdings at a proposed $8.1 billion valuation, one of the largest...read more
Phase 2 oncology biotech Edison Oncology Holding files and sets terms for a $25 million IPO
Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The Menlo Park, CA-based company plans to raise $25 million by offering 2.8 ...read more